Published Sep 21, 2022



PLUMX
Google Scholar
 
Search GoogleScholar


Mophine Owiti *

Angira Charles, PhD

Esther Osir, PhD

Article Details

Abstract

Background: Clinical efficacy of the use of antiretroviral drugs (ARVs) by HIV-negative individuals to prevent sexual transmission of HIV has been extensively reported. Global estimates indicate that adolescent girls and young women accounts for 68% of the new HIV acquisitions among young people. Oral Pre -exposure prophylaxis (PrEP) use in adolescent girls and young women remains suboptimal in Kenya despite Pre-Exposure Prophylaxis being scaled up nationally. Objective: To establish determinants for utilization of pre-exposure prophylaxis among adolescent girls and young women between 15 to 24 years of age in KisumuMunicipality, Kisumu County.  Design:A cross sectional study. Setting: Kajulu and Manyatta wards in Kisumu Municipality, Kisumu County, Kenya Subjects/Participants: Four Hundred and twenty two (422) participants drawn from a target population of 4000. The study used systematic sampling method. Semi-structured questionnaires were used to collect quantitative and qualitative data.  Results: There was statistically significant association between girls and young women aged 15-24 years preferring PrEP and utilization of pre-exposure prophylaxis at a 5% level of significance (p-value = 0.000<0.05, X2 =50.892a, df 4), an association between PrEP services being offered for free or at a cost and utilization of pre-exposure prophylaxis at a 5% level of significance (p-value = 0.000<0.05, 2 =89.799a, df 2) , an association  between nearest facility where girls and young women aged 15-24 years can access PrEP and utilization of PrEP  at 5% level of significance (p-value = 0.000<0.05, 2 =30.465 a, df 3),  association between quality of PrEP services in health facilities and utilization of PrEP was found to be statistically significant at a 5% level of significance (p value=0.011<0.05, 2 =,13.111adf 4), an association between recommendation/strategies given by respondents to improve uptake of PrEP and utilization of PrEP was statistically significant at 5% level of significance (p-value = 0.000<0.05, 2 =,70.476adf 4), an association between community talking about PrEP and utilization of PrEP was found to be statistically significant at a 5% level of significance (p-value = 0.004<0.05, 2 =8.515a, df 1), how the community portray the use of PrEP and utilization of PrEP was statistically significant at a 5% level of significance (p-value = 0.048<0.05, 2 =7.884aa, df 3) , association between social pressures within the community and utilization of PrEP was found to be statistically significant at a 5% level of significance (p value=0.001<0.05, 2 =,13.690adf 4) Conclusion: Socio-economic, Socio-Behavioural, Structural and Socio Culture played a greater role in determining utilization of pre-exposure prophylaxis among adolescent girls and young women between the ages of 15 to 24 years in Kisumu municipality, Kisumu County.

Keywords
References
1. UNAIDS Science Panel. Making the end of AIDS real: consensus building around what we mean by “epidemic control.” Geneva: UNAIDS; 2018 (http://www.unaids.org/sites/default/files/media_asset/glion_oct2017_meeting
_report_en.pdf, accessed 4 July 2019).
2. UNAIDS. 2016. “HIV Prevention among Adolescent Girls and Young Women.”
3. Young, Ingrid, Paul Flowers, and Lisa M. McDaid. 2014. “Barriers to Uptake and Use of Pre-Exposure Prophylaxis (PrEP) among Communities Most Affected by HIV in the UK: Findings from a Qualitative Study in Scotland.” BMJ Open 4(11): 1–8.
4. Arnold, Trisha et al. 2017. “Social, Structural, Behavioral and Clinical Factors Influencing Retention in Pre-Exposure Prophylaxis (PrEP) Care in Mississippi.” PLoS ONE 12(2): 1–10.
5. Ministry of Health, Kenya National AIDS report 2018
6. Ministry of Health, Kenya AIDS Indicators survey 2012-2013
7. Dellar, R, Dlamini. S, Karim. Q, Adolescent girls and young women: key populations for HIV epidemic control, Published 1 February 2015Medicine, Journal of the International AIDS Society
8. UNAIDS, Joint united Nation programme on HIV, 2015
9. PEPFAR Annual report to Congress 2015
10. Investing to End Epidemics: The Global Fund Strategy 2017-2022
11. LoVette A, Kuo C, Giovenco D, Hoare J, Underhill K, Operario D. Pre-exposure prophylaxis as an opportunity for engagement in HIV prevention among South African adolescents. SAHARA J. 2022 Dec; 19(1):1-7. doi: 10.1080/17290376.2021.2016479. PMID: 35135437; PMCID:PMC88432
04.
12. Gray, Megan E, Sheela V Shenoi, and Rebecca Dillingham. 2018. “Pre-Exposure Prophylaxis as HIV Prevention in High-Risk Adolescents.” 2(1): 5–10.
13. Mayer, K.H., Agwu, A. & Malebranche, D. Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review. Adv Ther 37, 1778–1811 (2020). https://doi.org/10.1007/s12325-020-01295-0
14. ATHENA. 2017. “A Review of the Pre-Exposure Prophylaxis (PrEP) Research and Evidence Landscape in Kenya and Uganda for Adolescent Girls and Young Women.” (July).
15. Lim, Sin How et al. 2017. “Willingness to Use Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men in Malaysia: Findings from an Online Survey.” PLoS ONE 12(9): 1–19.
16. Draft, Final, and Final Draft. 2016. “Guidelines for Expanding Combination Prevention and Treatment Options for Sex Workers : Oral Pre-Exposure Prophylaxis (PrEP) and Test and Treat (T & T).” (May).
Section
Review Articles